Kyiv City Clinical Oncology Center

ROR: 0555ajd25

OpenAlex ID: I4210147449

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

2019 · Luis Paz-Ares, Mikhail Dvorkin, et al. · The Lancet · 2,281

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

2014 · Richard S Finn, John P Crown, et al. · The Lancet Oncology · 1,894

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

2020 · Jonathan W Goldman, Mikhail Dvorkin, et al. · The Lancet Oncology · 688

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

2023 · Kim N. Chi, Dana Rathkopf, et al. · Journal of Clinical Oncology · 351

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

2022 · L. Paz-Ares, Y. Chen, et al. · ESMO Open · 346

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

2020 · Richard S. Finn, Katalin Boer, et al. · Breast Cancer Research and Treatment · 171

PDF

Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations.

2022 · Kim N. Chi, Dana E. Rathkopf, et al. · Journal of Clinical Oncology · 128

Regional hyperthermia combined with radiotherapy for uterine cervical cancers: A multi-institutional prospective randomized trial of the international atomic energy agency

2004 · Arumugam Vasanthan, Michihide Mitsumori, et al. · International Journal of Radiation Oncology*Biology*Physics · 123

Hypoxia, tumour-associated macrophages, microvessel density, VEGF and matrix metalloproteinases in human gastric cancer: interaction and impact on survival

2011 · Sergej Osinsky, Larissa Bubnovskaya, et al. · Clinical & Translational Oncology · 73

Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18).

2017 · Richard S. Finn, John Crown, et al. · Journal of Clinical Oncology · 67

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer.

2009 · A. Brufsky, I. Bondarenko, et al. · Cancer Research · 67

Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study

2020 · Jonathan W. Goldman, Marina Chiara Garassino, et al. · Lung Cancer · 57

PDF

Regional hyperthermia combined with radiotherapy for locally advanced non-small cell lung cancers: a multi-institutional prospective randomized trial of the International Atomic Energy Agency

2007 · Michihide Mitsumori, Zeng Zhi-Fan, et al. · International Journal of Clinical Oncology · 56

Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)

2014 · Richard S. Finn, John P. Crown, et al. · Cancer Research · 51

Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.

2020 · Luis G. Paz-Ares, Mikhail Dvorkin, et al. · Journal of Clinical Oncology · 48

LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN

2020 · J.W. Goldman, M.C. Garassino, et al. · Annals of Oncology · 32

PDF

Сd44+/cd24− Markers of Cancer Stem Cells in Patients With Breast Cancer of Different Molecular Subtypes

2015 · V F Chekhun, T V Zadvorny, et al. · Experimental Oncology · 32

Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia

2019 · Cornelius F. Waller, Gopinath M. Ranganna, et al. · Annals of Hematology · 25

PDF

Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non–Small-Cell Lung Cancer

2016 · David E. Gerber, David R. Spigel, et al. · Clinical Lung Cancer · 23

PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study

2019 · L. Paz-Ares, Y. Chen, et al. · Journal of Thoracic Oncology · 21

Breast cancer immunohistochemical features in young women with BRCA 1/2 mutations.

2009 · L M Zakhartseva, N G Gorovenko, et al. · PubMed · 21

PDF

The frequency of BRCA1 founder mutation c.5266dupC (5382insC) in breast cancer patients from Ukraine

2015 · Ielizaveta Gorodetska, Svitlana Serga, et al. · Hereditary Cancer in Clinical Practice · 17

PDF

Tumor microenvironment and metabolic factors: contribution to gastric cancer

2020 · L. Bubnovskaya, D. Osinsky · Experimental Oncology · 16

PDF

First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes.

2020 · Yuanbin Chen, Luis G. Paz-Ares, et al. · Journal of Clinical Oncology · 15

ASSOCIATION OF CD44+CD24−/low WITH MARKERS OF AGGRESSIVENESS AND PLASTICITY OF CELL LINES AND TUMORS OF PATIENTS WITH BREAST CANCER

2017 · V F Chekhun, N Yu Lukianova, et al. · Experimental Oncology · 15

Works count: 268

Citation count: 12,890